D Borden Lacy Selected Research

Infections

10/2023	Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
1/2023	Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to Clostridioides difficile toxin-mediated mitochondrial damage.
1/2023	Increased intestinal permeability and downregulation of absorptive ion transporters Nhe3, Dra, and Sglt1 contribute to diarrhea during Clostridioides difficile infection.
1/2022	Glucosyltransferase-dependent and independent effects of Clostridioides difficile toxins during infection.
1/2021	Clostridioides difficile infection induces a rapid influx of bile acids into the gut during colonization of the host.
1/2021	Murine Intrarectal Instillation of Purified Recombinant Clostridioides difficile Toxins Enables Mechanistic Studies of Pathogenesis.
1/2020	Structural analysis of the Legionella pneumophila Dot/Icm type IV secretion system core complex.
1/2020	Structural insights into the transition of Clostridioides difficile binary toxin from prepore to pore.
1/2020	Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease.
1/2020	Structural elucidation of the Clostridioides difficile transferase toxin reveals a single-site binding mode for the enzyme.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Borden Lacy Research Topics

Disease

14	Infections 10/2023 - 10/2013
8	Diarrhea 10/2023 - 01/2012
6	Necrosis 01/2022 - 01/2012
6	Clostridium Infections 01/2021 - 03/2014
5	Inflammation (Inflammations) 12/2016 - 11/2013
4	Anthrax 04/2013 - 05/2004
3	Pseudomembranous Enterocolitis (Pseudomembranous Colitis) 01/2023 - 06/2015
3	Edema (Dropsy) 04/2004 - 01/2002
2	Cross Infection (Nosocomial Infection) 10/2023 - 01/2012
2	Stomach Neoplasms (Stomach Cancer) 01/2020 - 10/2007
2	Reinfection 01/2017 - 01/2016
2	Neoplasms (Cancer) 05/2004 - 04/2004
1	Communicable Diseases (Infectious Diseases) 01/2021
1	RNA Virus Infections 01/2019
1	Photosensitivity Disorders (Photodermatitis) 01/2017
1	Soft Tissue Infections 01/2017
1	Sepsis (Septicemia) 03/2016
1	Bacteremia 10/2013
1	Paralysis (Palsy) 12/2008
1	Peptic Ulcer (Peptic Ulcers) 10/2007

Drug/Important Bio-Agent (IBA)

17	trimethylaminocarboxyldihydroboran (TCDB)IBA 10/2023 - 01/2012
8	Anti-Bacterial Agents (Antibiotics)IBA 10/2023 - 01/2012
6	Proteins (Proteins, Gene)FDA Link 10/2023 - 04/2004
4	AntigensIBA 10/2007 - 05/2002
3	GlucosyltransferasesIBA 01/2022 - 01/2016
3	anthrax toxin (anthrax lethal factor)IBA 05/2004 - 01/2002
2	Virulence Factors (Pathogenicity Factors)IBA 09/2023 - 04/2013
2	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2022 - 11/2013
2	EnzymesIBA 01/2021 - 11/2013
2	Type IV Secretion SystemsIBA 01/2020 - 01/2020
2	Amino Acids FDA Link 01/2016 - 04/2004
2	Clostridium difficile toxB proteinIBA 11/2013 - 01/2012
2	anthrax toxin receptorsIBA 05/2004 - 04/2004
1	ChloridesIBA 01/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2023
1	Chloride Channels (Chloride Channel)IBA 01/2023
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2021
1	Bile Acids and Salts (Bile Acids)IBA 01/2021
1	Nucleic AcidsIBA 01/2021
1	Calcium Channels (Calcium Channel)IBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2019
1	coproporphyrin IIIIBA 01/2017
1	Coproporphyrinogen Oxidase (Coproporphyrinogen III Oxidases)IBA 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	GTP Phosphohydrolases (GTPases)IBA 12/2016
1	Leukocidins (Leukocidin)IBA 03/2016
1	Monomeric GTP-Binding ProteinsIBA 01/2016
1	Anti-Infective Agents (Microbicides)IBA 01/2016
1	Cytotoxins (Cytolysins)IBA 11/2013
1	leukotoxinIBA 10/2013
1	Chemokine ReceptorsIBA 10/2013
1	NeurotoxinsIBA 12/2008
1	Type V Secretion SystemsIBA 10/2007
1	MetalsIBA 04/2004

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2012
1	Fecal Microbiota Transplantation 01/2021
1	Ambulatory Care (Outpatient Care) 01/2017